Novel aimp1 protein fragment and hair growth-promoting composition containing same as active ingredient

ABSTRACT

The present invention relates to novel fragments of AIMP1 protein and a composition for improving alopecia and promoting hair growth comprising the same, more specifically it relates to a polypeptide consisting of 4 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28th to 31st amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1, or a polypeptide consisting of an amino acid sequence having 70% or more sequence homology with the polypeptide; a polynucleotide encoding the polypeptide; a pharmaceutical, cosmetic and food composition for improving alopecia and promoting hair growth comprising the polypeptide.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application is a U.S. National Phase Application under 35 U.S.C. §371 of International Patent Application No. PCT/KR2017/008078, filedJul. 27, 2017, and claims priority to KR 10-2016-0096256, filed Jul. 28,2016, all of which are incorporated by reference in their entireties.The International Application was published on Feb. 1, 2018 asInternational Publication No. WO/2018/021839A1.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Jan. 24, 2019, isnamed 10524_007398-US0_SEQLST.txt and is 22 kilobytes in size.

TECHNICAL FIELD

The present invention relates to novel fragments of AIMP1 protein and acomposition for improving alopecia and promoting hair growth comprisingthe same, more specifically it relates to a polypeptide consisting of 4to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO:1, wherein the polypeptide comprises the 28^(th) to 31^(st) amino acidresidue (KEKA) of amino acid sequence of SEQ ID NO: 1, or a polypeptideconsisting of an amino acid sequence having 70% or more sequencehomology with the polypeptide; a polynucleotide encoding thepolypeptide; a pharmaceutical, cosmetic and food composition forimproving alopecia and promoting hair growth comprising the polypeptide.

BACKGROUND ART

The present application claims priority from and the benefit of KoreanPatent Application No. 10-2016-0096256 filed on Jul. 28, 2016, which ishereby incorporated by reference for all purposes as if fully set forthherein.

The pharmaceutical industry is changing from the development of naturalproducts or chemical synthetic medications in the past to thedevelopment of protein or peptide drugs. Protein is the basic substancein the function and structure of life, and it is estimated that theprotein constituting the human body is more than one million. It hasbeen directly related to diseases and has become an important researchsubject for the development of therapeutic drugs. Protein or peptidedrugs using them have been evaluated as innovations in pharmaceuticalsbecause they have fewer side effects and are more effective thansynthetic drugs. Currently, the importance of biomedicines in thepipeline of major pharmaceutical companies is increasing, but there aremajor technical problems until the launch of certain biomedicines suchas peptides. Specifically, improvement of delivery technique,development of peptide with increased stability and half-life, andlong-chain peptide synthesis are obstacles to commercialization.Peptides are made up of about 50 amino acids or less. It is known thatto be successful as a peptide drug, it is important to find a peptidehaving short sequence and activity. If the peptide length is long, thesynthesis cost is high and the production is not easy, and it is knownthat there is an absorption problem in human body.

Meanwhile, in animals including humans, hair follicles are subjected toseveral degeneration and regeneration processes from the time of thefetal development through the whole life. In the case of human hairgrowth, hair follicles continue to grow from the newborn to theadolescent period, and the hair becomes thicker and thicker. Hairfollicles are composed of several types of cells, such as epithelialcells and mesenchymal cells. Mesenchymal cells act as inductiveorganizers of the fetal and postnatal hair follicles. Follicle germcells are bulbar matrix cells that are responsible for most mitoticproliferation in hair follicles. During the period of generation, cellsin the bulb matrix migrate upwards and proliferate and differentiateinto hair matrix, inner and outer sheath cells. The hair matrix grouplocated on the central axis of the hair follicle continues todifferentiate into cells that make up the medulla, hair cortex and haircuticle. These cells continue to move upward with keratinization of thehair cortex and cuticle cells essential for hair formation inproliferating hair follicles.

The hair cycle is divided into three stages: 1) Anagen which is activedevelopment phase during the hair follicle cycle, 2) Catagen, and 3)Telogen. The duration of each step depends on the individual age,hormonal factors, nutritional and health status, and geneticpredisposition. Growth factors involved in promoting hair growth havenot yet been clarified. Of the 100,000 to 150,000 scalp hairs in humanadults, it is known that about 90% are in the growth phase (anagen) andthe remaining 10% are in the resting phase (telogen). It is known thatabout 500 to 1000 hard hairs are lost every day. In humans, hair growthrate is slightly different depending on the body part, which is 0.44mm/day for scalp hairs and 0.27 mm/day for beards or body hairs. Inanimals such as rats, hair cycle changes are synchronized, so that hairsof all areas are known to be in the same activity state. In rats, thefirst cycle of hair growth begins quickly after birth and lasts untilapproximately 21 days after birth. And, the second cycle starts about 35days after birth. Previously, young rats (8 to 12 days of age) have beenused as anticancer-induced alopecia models. It is known that micetreated with anticancer drugs in the first hair growth cycle totallylose hair within 10 days. In this case, hair loss state remainedunchanged until the second hair growth cycle begun. Thus, in rats, ittook 20-30 days to recover from alopecia.

Hair loss or alopecia is a disease in which hair is lost. Hair lossduring alopecia is not limited to scalp hair, and may occur in any partof the body. Various types of alopecia are known, including alopeciaareata, androgenetic alopecia, postmenopausal alopecia, female patternalopecia, seborrheic alopecia, alopecia pityroides, senile alopecia,cancer-induced alopecia, radiation-induced alopecia, alopecia due totrichotillomania, and postpartum alopecia, etc. The hair growthpromoting therapies known to date have been reported to have limitedefficacy or side effects.

Although alopecia itself does not endanger life, because it bringsserious psychological stress related to appearance, it is necessary todevelop a new therapeutic agent that can effectively promote hairgrowth, alleviate and treat alopecia safely, but have fewer sideeffects.

DETAILED DESCRIPTION OF THE INVENTION Technical Problem

Accordingly, the present inventors have confirmed that a specificfragment of the AIMP1 protein exhibits excellent effect on promotinghair growth, hair loss improvement, improving and treating alopecia invivo, thereby completing the present invention.

Therefore, an aspect of the present invention is to provide apolypeptide consisting of 4 to 21 consecutive amino acids from the aminoacid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence ofSEQ ID NO: 1, or a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

Another aspect of the present invention is to provide a polypeptideconsisting of amino acid sequence selected from the group consisting ofSEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13,SEQ ID NO: 14 and SEQ ID NO: 15, or a polypeptide consisting of an aminoacid sequence having 70% or more sequence homology with the polypeptide.

Another aspect of the present invention is to provide a polynucleotideencoding the polypeptide.

Another aspect of the present invention is to provide a pharmaceuticalcomposition for promoting hair growth, promoting proliferation of hairfollicle stem cells, or preventing and treating alopecia comprising oneor more polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

It is also to provide a pharmaceutical composition for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia consisting of one or more polypeptideas an active ingredient selected from the group consisting of apolypeptide consisting of 4 to 21 consecutive amino acids from the aminoacid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence ofSEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

It is also to provide a pharmaceutical composition for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia consisting essentially of one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

Another aspect of the present invention is to provide the pharmaceuticalcomposition for promoting hair growth, promoting proliferation of hairfollicle stem cells, or preventing and treating alopecia, wherein thepolypeptide consists of an amino acid sequence selected from the groupconsisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9,SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.

Another aspect of the present invention is to provide the pharmaceuticalcomposition for promoting hair growth, promoting proliferation of hairfollicle stem cells, or preventing and treating alopecia, wherein thecomposition further comprises a compound or pharmaceutically acceptablesalt thereof selected from the group consisting of minoxidil,cromakalin, pinacidil, naminidil, diphenylcyclopropenone, tricomin,cyproterone acetate, danazol, flutamide; 5-alpha reductase inhibitorsselected from the group consisting of finasteride, turosteride,LY-191704, MK-306 and dutasteride; striazines, benzopyrans,pyridinopyrans and thiane-1-oxides.

Another aspect of the present invention is to provide a cosmeticcomposition for promoting hair growth, or preventing and improvingalopecia comprising one or more polypeptide as an active ingredientselected from the group consisting of a polypeptide consisting of 4 to21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1,wherein the polypeptide comprises the 28^(th) to 31^(st) amino acidresidue (KEKA) of amino acid sequence of SEQ ID NO: 1, and a polypeptideconsisting of an amino acid sequence having 70% or more sequencehomology with the polypeptide.

It is also to provide a cosmetic composition for promoting hair growth,or preventing and improving alopecia consisting of one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

It is also to provide a cosmetic composition for promoting hair growth,or preventing and improving alopecia consisting essentially of one ormore polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

Another aspect of the present invention is to provide a food compositionfor promoting hair growth, or preventing and improving alopeciacomprising one or more polypeptide as an active ingredient selected fromthe group consisting of a polypeptide consisting of 4 to 21 consecutiveamino acids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

It is also to provide a food composition for promoting hair growth, orpreventing and improving alopecia consisting of one or more polypeptideas an active ingredient selected from the group consisting of apolypeptide consisting of 4 to 21 consecutive amino acids from the aminoacid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence ofSEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

It is also to provide a food composition for promoting hair growth, orpreventing and improving alopecia consisting essentially of one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

Another aspect of the present invention is to provide use of one or morepolypeptide selected from the group consisting of a polypeptideconsisting of 4 to 21 consecutive amino acids from the amino acidsequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th)to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ IDNO: 1, and a polypeptide consisting of an amino acid sequence having 70%or more sequence homology with the polypeptide for preparing an agentfor promoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia.

Another aspect of the present invention is to provide a method forpromoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia, the method comprisingadministering to a subject in need thereof an effective amount ofcomposition comprising one or more polypeptide as an active ingredientselected from the group consisting of a polypeptide consisting of 4 to21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1,wherein the polypeptide comprises the 28^(th) to 31^(st) amino acidresidue (KEKA) of amino acid sequence of SEQ ID NO: 1, and a polypeptideconsisting of an amino acid sequence having 70% or more sequencehomology with the polypeptide.

It is also to provide a method for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia, the method comprising administering to a subject in needthereof an effective amount of composition consisting of one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

It is also to provide a method for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia, the method comprising administering to a subject in needthereof an effective amount of composition consisting essentially of oneor more polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

Another aspect of the present invention is to provide a pharmaceuticalcomposition for promoting hair growth, promoting proliferation of hairfollicle stem cells, or preventing and treating alopecia comprising apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

It is also to provide a pharmaceutical composition for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia consisting of a polypeptide consistingof amino acid sequence of SEQ ID NO: 1 as an active ingredient.

It is also to provide a pharmaceutical composition for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia consisting essentially of a polypeptideconsisting of amino acid sequence of SEQ ID NO: 1 as an activeingredient.

Another aspect of the present invention is to provide a cosmeticcomposition for promoting hair growth, or preventing and improvingalopecia comprising a polypeptide consisting of amino acid sequence ofSEQ ID NO: 1 as an active ingredient.

It is also to provide a cosmetic composition for promoting hair growth,or preventing and improving alopecia consisting of a polypeptideconsisting of amino acid sequence of SEQ ID NO: 1 as an activeingredient.

It is also to provide a cosmetic composition for promoting hair growth,or preventing and improving alopecia consisting essentially of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

Another aspect of the present invention is to provide a food compositionfor promoting hair growth, or preventing and improving alopeciacomprising a polypeptide consisting of amino acid sequence of SEQ ID NO:1 as an active ingredient.

It is also to provide a food composition for promoting hair growth, orpreventing and improving alopecia consisting of a polypeptide consistingof amino acid sequence of SEQ ID NO: 1 as an active ingredient.

It is also to provide a food composition for promoting hair growth, orpreventing and improving alopecia consisting essentially of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

Another aspect of the present invention is to provide use of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 forpreparing an agent for promoting hair growth, promoting proliferation ofhair follicle stem cells, or preventing and treating alopecia.

Another aspect of the present invention is to provide a method forpromoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia, the method comprisingadministering to a subject in need thereof an effective amount ofcomposition comprising a polypeptide consisting of amino acid sequenceof SEQ ID NO: 1 as an active ingredient.

It is also to provide a method for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia, the method comprising administering to a subject in needthereof an effective amount of composition consisting of a polypeptideconsisting of amino acid sequence of SEQ ID NO: 1 as an activeingredient.

It is also to provide a method for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia, the method comprising administering to a subject in needthereof an effective amount of composition consisting essentially of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

Technical Solution

In accordance with an aspect of the present invention, there is provideda polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, or a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

In accordance with another aspect of the present invention, there isprovided a polypeptide consisting of amino acid sequence selected fromthe group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ IDNO: 9, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, or a polypeptideconsisting of an amino acid sequence having 70% or more sequencehomology with the polypeptide.

In accordance with another aspect of the present invention, there isprovided a polynucleotide encoding the polypeptide.

In accordance with another aspect of the present invention, there isprovided a pharmaceutical composition for promoting hair growth,promoting proliferation of hair follicle stem cells, or preventing andtreating alopecia comprising one or more polypeptide as an activeingredient selected from the group consisting of a polypeptideconsisting of 4 to 21 consecutive amino acids from the amino acidsequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th)to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ IDNO: 1, and a polypeptide consisting of an amino acid sequence having 70%or more sequence homology with the polypeptide.

There is also provided a pharmaceutical composition for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia consisting of one or more polypeptideas an active ingredient selected from the group consisting of apolypeptide consisting of 4 to 21 consecutive amino acids from the aminoacid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence ofSEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

There is also provided a pharmaceutical composition for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia consisting essentially of one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

In accordance with another aspect of the present invention, there isprovided the pharmaceutical composition for promoting hair growth,promoting proliferation of hair follicle stem cells, or preventing andtreating alopecia, wherein the composition further comprises a compoundor pharmaceutically acceptable salt thereof selected from the groupconsisting of minoxidil, cromakalin, pinacidil, naminidil,diphenylcyclopropenone, tricomin, cyproterone acetate, danazol,flutamide; 5-alpha reductase inhibitors selected from the groupconsisting of finasteride, turosteride, LY-191704, MK-306 anddutasteride; striazines, benzopyrans, pyridinopyrans andthiane-1-oxides.

In accordance with another aspect of the present invention, there isprovided a cosmetic composition for promoting hair growth, or preventingand improving alopecia comprising one or more polypeptide as an activeingredient selected from the group consisting of a polypeptideconsisting of 4 to 21 consecutive amino acids from the amino acidsequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th)to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ IDNO: 1, and a polypeptide consisting of an amino acid sequence having 70%or more sequence homology with the polypeptide.

There is also provided a cosmetic composition for promoting hair growth,or preventing and improving alopecia consisting of one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

There is also provided a cosmetic composition for promoting hair growth,or preventing and improving alopecia consisting essentially of one ormore polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

In accordance with another aspect of the present invention, there isprovided a food composition for promoting hair growth, or preventing andimproving alopecia comprising one or more polypeptide as an activeingredient selected from the group consisting of a polypeptideconsisting of 4 to 21 consecutive amino acids from the amino acidsequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th)to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ IDNO: 1, and a polypeptide consisting of an amino acid sequence having 70%or more sequence homology with the polypeptide.

There is also provided a food composition for promoting hair growth, orpreventing and improving alopecia consisting of one or more polypeptideas an active ingredient selected from the group consisting of apolypeptide consisting of 4 to 21 consecutive amino acids from the aminoacid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence ofSEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

There is also provided a food composition for promoting hair growth, orpreventing and improving alopecia consisting essentially of one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

In accordance with another aspect of the present invention, there isprovided use of one or more polypeptide selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide for preparing an agent for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia.

In accordance with another aspect of the present invention, there isprovided a method for promoting hair growth, promoting proliferation ofhair follicle stem cells, or preventing and treating alopecia, themethod comprising administering to a subject in need thereof aneffective amount of composition comprising one or more polypeptide as anactive ingredient selected from the group consisting of a polypeptideconsisting of 4 to 21 consecutive amino acids from the amino acidsequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th)to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ IDNO: 1, and a polypeptide consisting of an amino acid sequence having 70%or more sequence homology with the polypeptide.

There is also provided a method for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia, the method comprising administering to a subject in needthereof an effective amount of composition consisting of one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

There is also provided a method for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia, the method comprising administering to a subject in needthereof an effective amount of composition consisting essentially of oneor more polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

In accordance with another aspect of the present invention, there isprovided a pharmaceutical composition for promoting hair growth,promoting proliferation of hair follicle stem cells, or preventing andtreating alopecia comprising a polypeptide consisting of amino acidsequence of SEQ ID NO: 1 as an active ingredient.

There is also provided a pharmaceutical composition for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia consisting of a polypeptide consistingof amino acid sequence of SEQ ID NO: 1 as an active ingredient.

There is also provided a pharmaceutical composition for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia consisting essentially of a polypeptideconsisting of amino acid sequence of SEQ ID NO: 1 as an activeingredient.

In accordance with another aspect of the present invention, there isprovided a cosmetic composition for promoting hair growth, or preventingand improving alopecia comprising a polypeptide consisting of amino acidsequence of SEQ ID NO: 1 as an active ingredient.

There is also provided a cosmetic composition for promoting hair growth,or preventing and improving alopecia consisting of a polypeptideconsisting of amino acid sequence of SEQ ID NO: 1 as an activeingredient.

There is also provided a cosmetic composition for promoting hair growth,or preventing and improving alopecia consisting essentially of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

In accordance with another aspect of the present invention, there isprovided a food composition for promoting hair growth, or preventing andimproving alopecia comprising a polypeptide consisting of amino acidsequence of SEQ ID NO: 1 as an active ingredient.

There is also provided a food composition for promoting hair growth, orpreventing and improving alopecia consisting of a polypeptide consistingof amino acid sequence of SEQ ID NO: 1 as an active ingredient.

There is also provided a food composition for promoting hair growth, orpreventing and improving alopecia consisting essentially of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

In accordance with another aspect of the present invention, there isprovided use of a polypeptide consisting of amino acid sequence of SEQID NO: 1 for preparing an agent for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia

In accordance with another aspect of the present invention, there isprovided a method for promoting hair growth, promoting proliferation ofhair follicle stem cells, or preventing and treating alopecia, themethod comprising administering to a subject in need thereof aneffective amount of composition comprising a polypeptide consisting ofamino acid sequence of SEQ ID NO: 1 as an active ingredient.

There is also provided a method for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia, the method comprising administering to a subject in needthereof an effective amount of composition consisting of a polypeptideconsisting of amino acid sequence of SEQ ID NO: 1 as an activeingredient.

There is also provided a method for promoting hair growth, promotingproliferation of hair follicle stem cells, or preventing and treatingalopecia, the method comprising administering to a subject in needthereof an effective amount of composition consisting essentially of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

Hereinafter, the present invention will be described in detail.

The term “KEKA residue”, “KEKA sequence”, or “KEKA region” in thepresent invention can be used interchangeably and refers to the 33^(th)to 36^(th) amino acid region in the full length amino acid sequence ofAIMP1 protein represented by SEQ ID NO: 16, SEQ ID NO: 33, SEQ ID NO: 34or SEQ ID NO: 35. And the region corresponds to the 28^(th) to 31^(st)amino acid residue in the polypeptide of SEQ ID NO: 1 (or referred to as“Neo-Pep”) which is the example of the hair growth promoting activefragment provided by the present invention.

Hereinafter, the polypeptide provided by the present invention is afragment derived from AIMP1 protein, which comprises the 28th to 31stamino acid (KEKA) region in the amino acid sequence of SEQ ID NO: 1 andhas remarkably excellent effect on promoting hair growth andproliferation of hair follicle stem cells. It is disclosed in thepresent invention for the first time that the KEKA region of AIMP1 isessential for promoting hair growth, promoting proliferation of hairfollicle stem cells, preventing, improving or treating alopecia.

Therefore, the present invention provides a polypeptide consisting of 4to 21 consecutive amino acids, preferably 10 to 21 consecutive aminoacids, more preferably 15 to 20 consecutive amino acids from the aminoacid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence ofSEQ ID NO: 1, or a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

Preferably, the polypeptide of the present invention consists of anamino acid sequence selected from the group consisting of SEQ ID NO: 6,SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14and SEQ ID NO: 15.

As used herein, the terms “polypeptide”, “peptide” and “protein” areused interchangeably and refer to polymers of amino acid residues ascommonly found in natural state proteins.

The one letter (triplet) of amino acids used herein means the followingamino acids according to standard abbreviations in the biochemistry: A(Ala): alanine; C (Cys): cysteine; D (Asp): aspartic acid; E (Glu):glutamic acid; F (Phe): phenylalanine; G (Gly): glycine; H (His):histidine; I (IIe): isoleucine; K (Lys): lysine; L (Leu): leucine; M(Met): methionine; N (Asn): Asparagine; O (Ply): pyrrolysine; P (Pro):proline; Q (Gln): Glutamine; R (Arg): arginine; S (Ser): serine; T(Thr): threonine; U (Sec): selenocysteine, V (Val): valine; W (Trp):tryptophan; Y (Tyr): Tyrosine.

In the present invention, ‘AIMP1 (ARS-interacting multi-functionalprotein 1) protein’ was firstly known as p43 protein and was renamed asAIMP1 (Kim S H et al., Trends in Biochemical Sciences, 30: 569-574,2005). AIMP1 binds to a multi-tRNA synthetase complex to enhance thecatalytic activity of the multi-tRNA synthetase. The specific sequenceof the AIMP1 protein of the present invention is not particularlylimited as long as it is known in the art and can be preferably humanAIMP1. Three SNPs of the AIMP1 protein are known (see NCBI SNPdatabase): 79th alanine (Ala) in the amino acid sequence of thefull-length AIMP1 (SEQ ID NO: 33 in the present specification) issubstituted with proline (Pro) (SNP Accession No. rs3133166, SEQ ID NO:16); 104th threonine (Thr) is substituted with alanine (Ala) (SNPAccession No. rs17036670, SEQ ID NO: 34); 117th threonine (Thr) issubstituted with alanine (Ala) (SNP Accession No. rs2230255, SEQ ID NO:35).

The polypeptide of the present invention, that is, polypeptideconsisting of 4 to 21 consecutive amino acids from the amino acidsequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28th to31st amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1,include functional equivalent thereof. The functional equivalent meanspolypeptide having at least 70% or more (70.0% to 99.9%), preferably 80%or more (80.0% to 99.9%), and more preferably 90% or more (90% to 99.9%)sequence homology (or identity) with the polypeptide of the presentinvention. More preferably, the functional equivalent means polypeptidehaving at least 70% or more, preferably 80% or more, and more preferably90% or more sequence homology (or identity) with the polypeptide of thepresent invention with constant (unchanged) sequence of KEKA region(sequence). For example, these include polypeptides having 70%, 71%,72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%,86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or100% sequence homology, and exhibits substantially the samephysiological activity as the polypeptide of the present invention.Herein, the term “substantially” means a state indicating a property ofa certain property to a whole or almost the same degree. Therefore, inthe present invention, “substantially the same physiological activity”means activity of promoting hair growth such as promoting the formationof hair follicle, increasing the number of hair follicle; promotingproliferation of hair follicle stem cells; or preventing, improving ortreating alopecia.

Most preferably, the functional equivalent can be a polypeptide havingleast 70%, preferably at least 80%, more preferably at least 90%sequence homology (or identity) with the polypeptide of the presentinvention with the constant sequence of KEKA region (sequence) andisoelectric point (PI) of 9 to 11.

In the present invention, “homology or identity” refers to the overallrelatedness between polymer molecules, such as polypeptide molecules.For example, calculation of homology/identity (%) between twopolypeptide sequences can be performed by aligning two sequences foroptimal comparison. Preferably, the length of the sequence arranged forcomparison purposes is at least 30%, at least 40%, at least 50%, atleast 60%, at least 70%, at least 80% %, at least 90%, or substantially100% of the reference sequence. Then, the amino acids at thecorresponding amino acid sites are compared with each other. If theamino acid located at the first sequence is identical to the amino acidat the corresponding site of the second sequence, the two sequences areidentical at that site. The identity (%) of the two sequences is afunction of the number of sites having amino acids common to the twosequences, taking into account the number and length of the gaps to beintroduced for optimal alignment between the two sequences. Thecomparison between two sequences and the determination of identity (%)can be performed through a mathematical algorithm. For example, ClustalW(Thompson et al., 1994) can be used to measure sequence identity valuesusing the following parameters: Pair Array Parameters—Method: Accurate,Matrix: PAM, Gap open penalty: 10.00, Gap extension penalty: 0.10;Multiple array parameters—Matrix: PAM, Gap open penalty: 10.00, delayidentity: 30, penalize end gaps: on, Gap separation distance: 0,Negative Matrix: no, gap extension penalty: 0.20, residue-specific gappenalties: on, hydrophilic gap penalty: on, hydrophilic residue:GPSNDQEKR. Sequence identity in a particular residue includes the sameresidue that is simply derivatized.

In the present invention, the term “substantially” means a stateindicating a property of a certain property to a whole or almost thesame degree. The term “substantially the same” in the present inventionis used related to the comparison between amino acid or nucleic acidsequences. For those of ordinary skill in the art to which the presentinvention pertains, two sequences will be understood to be“substantially identical” if they have identical residues atcorresponding sites. As is well known in the art, amino acid or nucleicacid sequences can be compared using a variety of algorithms, forexample, computer programs such as BLASTN for nucleic acid sequencecomparison, BLASTP, gapped BLAST or PSI-BLAST for amino acid sequencecomparison can be used. Examples of such computer programs are describedin the following references: Altschul et al., Basic local alignmentsearch tool, J. Mol. Biol., 215(3): 403-410, 1990; Altschul et al.,Methods in Enzymology; Altschul et al., Nucleic Acids Res. 25:3389-3402,1997; Baxevanis

, Bioinformatics: A Practical Guide to the Analysis of Genes andProteins, Wiley, 1998;

Misener et al., (eds.), Bioinformatics Methods and Protocols (Methods inMolecular Biology, Vol. 132), Humana Press, 1999. In addition tosearching for the same sequence, the computer programs described abovetypically provide a degree of identity. In two sequences, it isconsidered to be “substantially the same” sequences if at least 70%,preferably at least 80%, at least 85%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% or more of the residue at thecorresponding site over a certain length of residue is identical.Preferably, the “certain length of residue” can be a residue of at least1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,38,39, 40, 41, 42, 43, 44, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100,105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 160,165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230,235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300 ormore.

In the present invention, the term “corresponding” is often used todetermine the position/identity of the amino acid residues of a givenpolypeptide. As is conventional, residues in a polypeptide are oftendesignated using a canonical numbering system based on reference-relatedpolypeptides. Thus, for example, a “corresponding” amino acid in theresidue at the 190th position doesn't always have to be at the 190thposition in a particular amino acid chain, and one of ordinary skill inthe art will readily understand how to identify the “corresponding”amino acid.

The “functional equivalent” can be a polypeptide that is produced as aresult of addition, substitution or deletion of some amino acid sequenceof the polypeptide of the present invention. The substitution of theamino acid is preferably a conservative substitution. Examples ofconservative substitutions of amino acids present in nature are asfollows: aliphatic amino acids (Gly, Ala, Pro), hydrophobic amino acids(Ile, Leu, Val), aromatic amino acids (Phe, Tyr, Trp), acidic aminoacids (Asp, Glu), basic amino acids (His, Lys, Arg, Gln, Asn) and sulfurcontaining amino acids (Cys, Met). Also included in the functionalequivalent is variant in which a portion of the amino acid is deleted inthe amino acid sequence of the polypeptide of the present invention. Thedeletion or substitution of the amino acid is preferably located in aregion that is not directly related to the physiological activity of thepolypeptide of the present invention. In the present invention, theregion directly related to the physiological activity is a KEKA region,and the deletion or substitution can be located at a region other thanthe above-mentioned region. Also included are variants in which someamino acids are added at both ends or in the sequence of the amino acidof the polypeptide of the present invention. Also included in thefunctional equivalent of the present invention is protein or polypeptidederivatives in which some of the chemical structures of the proteins aremodified while maintaining the basic skeleton and physiological activityof the protein according to the present invention. This includes, forexample, structural modifications to alter the stability, shelfstability, volatility or solubility of the protein of the presentinvention.

In the present invention, sequence homology and identity are defined asthe percentage of amino acid residues of the candidate sequence relativeto the amino acid sequence of the polypeptide of the present inventionafter aligning the candidate sequence with the amino acid sequence ofthe polypeptide of the present invention and introducing a gap. Ifnecessary, conservative substitutions as part of sequence homology arenot considered to obtain maximum percent sequence homology. Also, theN-terminal, C-terminal or internal stretch, deletion or insertion of anamino acid sequence of a polypeptide of the invention is not interpretedas a sequence that affects sequence homology or identity. In addition,the sequence homology can be determined by standard methods used tocompare similar region of amino acid sequences of two proteins orpolypeptides. BLAST or such a computer program aligns two proteins orpolypeptides so that each amino acid is optimally matched (along thefull length sequence of one or two sequences or along the predictedregion of one or two sequences). The program provides default openingpenalty and default gap penalty, and provides scoring matrix such as aPAM250 (Standard Scoring Matrix; Dayhoff et al., In Atlas of ProteinSequence & lt; RTI ID=0.0 & gt; Structure, vol 5, supp 3, 1978). Forexample, percentage homogeneity can be calculated as follows: Aftermultiplying the total number of identical matches by 100 and dividing bythe sum of the length of a longer sequence in a matched span and thenumber of gaps that is introduced into the longer sequence to align thetwo sequences.

The polypeptides of the present invention can be constructed by geneticengineering methods. First, a polynucleotide sequence encoding thepolypeptide of the present invention is constructed according to aconventional method. The polynucleotide sequence can be constructed, forexample, by PCR amplification of a polynucleotide encoding the humanAIMP1 gene as a template using an appropriate primer. Alternatively, DNAsequences may be synthesized by standard methods known in the art, forexample, using an automated DNA synthesizer (commercially available fromBiosearch or Applied Biosystems Inc). The constructed polynucleotide isthen inserted into a vector comprising one or more expression controlsequence (e.g., promoters, enhancers, etc.) which is operatively linkedwith the polynucleotide so that controls the expression of base sequenceof the polynucleotide, followed by transform host cells with therecombinant expression vector. The resulting transgenic cells arecultured under a medium and conditions suitable for the expression ofthe DNA sequence, and collect substantially pure protein encoded by theDNA sequence from the culture. The collection means separating(isolating) and/or purifying the objective peptide using methods knownin the art (e.g. chromatography).

The term “substantially pure polypeptide or protein” means substantiallyfree of any other protein derived from the host cells. Geneticengineering methods for protein synthesis of the present invention canbe found in the following references: Maniatis et al., MolecularCloning; A laboratory Manual, Cold Spring Harbor laboratory, 1982;Sambrook et al., supra; Gene Expression Technology, Method inEnzymology, Genetics and Molecular Biology, Method in Enzymology,Guthrie & Fink (eds.), Academic Press, San Diego, Calif., 1991; andHitzeman et al., J. Biol. Chem., 255:12073-12080, 1990.

The polypeptides of the present invention can also be chemicallysynthesized by techniques known in the art (Creighton, Proteins:Structures and Molecular Principles, WH Freeman and Co., NY (1983)).That is, the polypeptides of the present invention can be prepared usingconventional stepwise liquid or solid phase synthesis, fractionalcondensation, F-MOC or T-BOC chemistry (Chemical Approaches to theSynthesis of Peptides and Proteins, Williams et al. , Eds., CRC Press,Boca Raton, Fla., (1997); A Practical Approach, Atherton & Sheppard,Eds., IRL Press, Oxford, England, (1989)). A preferred method ofpreparation is solid phase synthesis. The polypeptide of the presentinvention can be synthesized by a condensation reaction betweenprotected amino acids in a conventional solid-phase method, sequentiallyproceeding according to the amino acid sequence identified starting fromthe C-terminal. After the condensation reaction, the protecting groupand the carrier to which the C-terminal amino acid is linked can beremoved by a known method such as acid decomposition or aminolysis. Theabove-mentioned peptide synthesis methods are described in detail in therelevant book (Gross and Meienhofer's, The Peptides, vol 2, AcademicPress, 1980).

The protein produced by the genetic engineering method or the chemicallysynthesized protein can be separated and purified by various methodsknown in the art such as extraction, recrystallization, variouschromatography (gel filtration, ion exchange, precipitation, adsorption,reverse phase), electrophoresis, counter current distribution method,etc.

In addition, the present invention provides a polynucleotide encodingthe polypeptide of the present invention, that is a polypeptideconsisting of 4 to 21 consecutive amino acids from the amino acidsequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th)to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ IDNO: 1. The polynucleotide is not particularly limited in its basicconstitution as long as it encodes the above-mentioned polypeptide ofthe present invention. Preferably, the polynucleotide encoding thepolypeptide of the invention consists of nucleotide sequence selectedfrom the group consisting of SEQ ID NO: 22 (encoding the N5 polypeptideof SEQ ID NO: 6), SEQ ID NO: 23 (encoding the N6 polypeptide of SEQ IDNO: 7), SEQ ID NO: 24 (encoding the N7 polypeptide of SEQ ID NO: 8), SEQID NO: 25 (encoding the N8 polypeptide of SEQ ID NO: 9), SEQ ID NO: 29(encoding the N12 polypeptide of SEQ ID NO: 13), SEQ ID NO: 30 (encodingthe N13 polypeptide of SEQ ID NO: 14) and SEQ ID NO: 31 (encoding theN14 polypeptide of SEQ ID NO: 15).

In the present invention, “polynucleotide”, “nucleic acid” refers to adeoxyribonucleotide (DNA) or a ribonucleotide (RNA) in the form of asingle-stranded or double-stranded nucleic acid. Unless otherwiselimited, it also includes known analogs of natural nucleotides thathybridize to nucleic acids in a manner similar to naturally occurringnucleotides.

In addition, the present invention provides a pharmaceutical compositionfor promoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia comprising one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

The present invention also provides a pharmaceutical composition forpromoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia consisting of one or morepolypeptide as an active ingredient selected from the group consistingof a polypeptide consisting of 4 to 21 consecutive amino acids from theamino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprisesthe 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequenceof SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequencehaving 70% or more sequence homology with the polypeptide.

The present invention also provides a pharmaceutical composition forpromoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia consisting essentially of oneor more polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

Preferably, in the pharmaceutical composition of the present invention,the polypeptide can be a polypeptide consisting of an amino acidsequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO:7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ IDNO: 15.

In addition, the present invention provides a pharmaceutical compositionfor promoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia comprising a polypeptideconsisting of amino acid sequence of SEQ ID NO: 1 as an activeingredient.

The present invention also provides a pharmaceutical composition forpromoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia consisting of a polypeptideconsisting of amino acid sequence of SEQ ID NO: 1 as an activeingredient.

The present invention also provides a pharmaceutical composition forpromoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia consisting essentially of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

In the present invention, the term “hair” refers to scalp hair, hair,facial hair and/or body hair, which broadly includes scalp hair,eyelashes, eyebrows, mustache, beard, ear hair, nose hair, chest hair,pubic hair, assistant hair, and the likes, but is not limited thereto.

In the present invention, the term “promoting hair growth” includespromoting hair production and growth in the hair follicle as well aspromoting the growth of existing hair, and includes promoting hairfollicle formation, structural stabilization of hair follicles andfacilitating nutrient and oxygen supply, faster induction of anagenphase and/or prolongation of the main anagen phase (growth phase) ofhair cycle and/or increase in hair growth rate and/or increase in widthof hair, and this includes, but is not limited to, induction orimprovement of hair growth and making it more visible to the eye.

In the present invention, “hair loss or alopecia” is used to mean allthe symptoms of hair loss, regardless of the specific biologicalmechanism of hair loss. As used herein, “preventing and treatingalopecia” is used broadly to refer to prevention, improvement, andtreatment of alopecia.

The polypeptide according to the invention can be used as itself or inthe form of a salt, preferably a pharmaceutically acceptable salt. Theterm “pharmaceutically acceptable” as used herein means physiologicallyacceptable, does not inhibit the action of the active ingredient whenadministered to humans, and does not usually cause an allergic reactionsuch as gastrointestinal disorder, dizziness or similar side effects. Asthe salt, an acid addition salt formed by a pharmaceutically acceptablefree acid is preferable, and as the free acid, organic acid andinorganic acid can be used. The organic acids include, but are notlimited to, citric acid, acetic acid, lactic acid, tartaric acid, maleicacid, fumaric acid, formic acid, propionic acid, oxalic acid,trifluoracetic acid, benzoic acid, gluconic acid, methosulfonic acid,glycolic acid, succinic acid, 4-toluensulfonic acid, glutamic acid andaspartic acid. The inorganic acid includes, but is not limited to,hydrochloric acid, bromic acid, sulfuric acid, and phosphoric acid.

The pharmaceutical composition of the present invention can be variouslyformulated according to the route of administration by a method known inthe art together with a pharmaceutically acceptable carrier forpromoting hair growth promoting and/or preventing and treating alopecia.The carriers include all types of solvents, dispersion media,oil-in-water or water-in-oil emulsions, aqueous compositions, liposomes,microbeads and microsomes.

The route of administration can be oral or parenteral. The parenteraladministration methods include, but are not limited to, intravenous,intramuscular, intraarterial, intramedullary, intrathecal, intracardiac,transdermal, subcutaneous, intraperitoneal, intranasal, enteral,topical, sublingual or rectal administration.

When the pharmaceutical composition of the present invention is to beorally administered, the pharmaceutical composition of the presentinvention can be formulated into various types such as powder, granule,tablet, pill, sugar, capsule, liquid, gel, syrup, suspension, wafer, andthe like. Examples of suitable carriers include saccharides includinglactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol andmaltitol, and starches including corn starch, wheat starch, rice starchand potato starch, and cellulose such as cellulose, methyl cellulose,sodium carboxymethyl cellulose and hydroxypropylmethyl cellulose, andfillers such as gelatin, polyvinyl pyrrolidone and the like. Inaddition, crosslinked polyvinylpyrrolidone, agar, alginic acid or sodiumalginate may optionally be added as a disintegrant. Furthermore, thepharmaceutical composition can further comprise an anti-coagulant, alubricant, a wetting agent, a flavoring agent, an emulsifying agent andan antiseptic agent.

In addition, when administered parenterally, the pharmaceuticalcomposition of the present invention can be formulated in accordancewith methods known in the art in the form of injections, transdermaldrugs, and nasal inhalers together with suitable non-oral carriers. Inthe case of the injections, they must be sterilized and protected fromcontamination of microorganisms such as bacteria and fungi. Examples ofsuitable carriers for injections include, but are not limited to,solvents or dispersion media containing water, ethanol, polyols (such asglycerol, propylene glycol and liquid polyethylene glycol, etc.),mixtures thereof and/or vegetable oils. More preferably, suitablecarriers include, but are not limited to, Hank's solution, Ringer'ssolution, phosphate buffered saline (PBS) containing triethanolamine orisotonic solutions such as sterile water for injection, 10% ethanol, 40%propylene glycol and 5% dextrose. In order to protect the injectionsfrom microbial contamination, various antibacterial and antifungalagents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosaland the like may be further included. In addition, the injections can inmost cases further comprise an isotonic agent such as sugar or sodiumchloride.

Examples of transdermal administration forms include ointments, creams,lotions, gels, solutions for external use, pastes, liniments, and airrolls. In the above, transdermal administration means that thepharmaceutical composition is locally administered to the skin, wherebyan effective amount of the active ingredient contained in thepharmaceutical composition is delivered into the skin. For example, thepharmaceutical composition of the present invention can be prepared intoa injectable formulation, which may be administered by pricking the skinlightly with a 30-gauge thin injection needle or by directly applying itto the skin. These formulations are described in a commonly knownformulary article in pharmaceutical chemistry (Remington'sPharmaceutical Science, 15th Edition, 1975, Mack Publishing Company,Easton, Pa.).

In the case of an inhalation administration form, the polypeptide usedin accordance with the present invention can be conveniently deliveredin the form of aerosol spray from pressurized pack or a fog machineusing a suitable propellant, such as dichlorofluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide orother suitable gases. In the case of a pressurized aerosol, the dosageunit may be determined by providing a valve that delivers a meteredamount. For example, gelatin capsules and cartridges for use in aninhaler or insufflator can be formulated to contain a compound and apowder mix of a suitable powder base such as lactose or starch.

As other pharmaceutically acceptable carriers, reference may be made tothose described in the following references (Remington's PharmaceuticalSciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).

The pharmaceutical composition according to the present invention canalso contain one or more buffers (e.g., saline or PBS), a carbohydrate(e.g., glucose, mannose, sucrose or dextran), an antioxidant, abacteriostatic, (e.g., EDTA or glutathione), an adjuvant (e.g., aluminumhydroxide), a suspending agent, a thickening agent and/or apreservative.

In addition, the pharmaceutical compositions of the present inventioncan be formulated using methods known in the art so as to provide rapid,sustained or delayed release of the active ingredient afteradministration to mammals.

In addition, the pharmaceutical composition of the present invention canbe administered alone or in combination with a known compound havingalopecia prevention or hair growth promoting effect. Such combinationtherapies include the methods of being included in the same compositionor administered simultaneously, and include administering thepolypeptide of the present invention at least once in the process of atreatment using one or more other alopecia treatment/hair growthpromoters, but is not limited thereto.

By “administration form” or “single administration form” herein is meanta physically discrete unit of the therapeutic protein for the patient tobe treated. Each treatment unit contains a pre-measured amount of activematerial to provide the desired therapeutic effect. However, the totaldosage of the therapeutic composition is determined by the attendingphysician within sufficient medical judgment.

Examples of a known compound having a alopecia prevention or hair growthpromoting effect that can be further used in combination with thepolypeptide of the present invention or a pharmaceutical compositioncomprising the polypeptide of the present invention include compounds orpharmaceutically acceptable salts thereof selected from the groupconsisting of minoxidil, cromakalin, pinacidil, naminidil,diphenylcyclopropenone, tricomin, cyproterone acetate, danazol,flutamide; 5-alpha reductase inhibitors selected from the groupconsisting of finasteride, turosteride, LY-191704, MK-306 anddutasteride; striazines, benzopyrans, pyridinopyrans andthiane-1-oxides, but not limited thereto.

In addition, the present invention provides a cosmetic composition forpromoting hair growth, or preventing and improving alopecia comprisingone or more polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

The present invention also provides a cosmetic composition for promotinghair growth, or preventing and improving alopecia consisting of one ormore polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

The present invention also provides a cosmetic composition for promotinghair growth, or preventing and improving alopecia consisting essentiallyof one or more polypeptide as an active ingredient selected from thegroup consisting of a polypeptide consisting of 4 to 21 consecutiveamino acids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

Preferably, in the cosmetic composition of the present invention, thepolypeptide can be a polypeptide consisting of an amino acid sequenceselected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ IDNO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.

In addition, the present invention provides a cosmetic composition forpromoting hair growth, or preventing and improving alopecia comprising apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

The present invention also provides a cosmetic composition for promotinghair growth, or preventing and improving alopecia consisting of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

The present invention also provides a cosmetic composition for promotinghair growth, or preventing and improving alopecia consisting essentiallyof a polypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

The cosmetic composition of the present invention can be prepared in anyformulation conventionally produced in the art, and it is also possibleto use a dermatologically acceptable medium or base in addition to thepolypeptide of the present invention, so that it can be prepared in theform of topical or systemic adjuvant that is commonly used in thedermatological field.

The cosmetic composition of the present invention can further comprisesadjuvant commonly used in the cosmetic or dermatology field, in additionto the polypeptide according to the present invention, such as a lipid,an organic solvent, a solubilizing agent, a thickening agent and agelling agent, a softening agent, an antioxidant, a suspending agent, astabilizer, a foaming agent, a perfuming agent, a surfactant, water,ionic or nonionic emulsifiers, a filler, a sequestrant and chelatingagent, a preservative, a vitamin, a blocking agent, a wetting agent, anessential oil, a dye, a pigment, a hydrophilic or lipophilic activeagent, a lipid vesicle or a any other ingredient used in cosmetics ordermatology. And the above ingredients can be added in amounts commonlyused in the field of dermatology.

Formulations of suitable cosmetic compositions include, for example,solutions, gels, solid or kneaded anhydrous products, emulsions obtainedby dispersing the oil phase in water, suspensions, microemulsions,microcapsules, microgranules or ionic (liposomes), form of a folliculardispersion, cream, skin, lotion, powder, ointment, spray or concealstick. It can also be prepared in the form of a foam or an aerosolcomposition further containing a compressed propellant. Examples of thecosmetic preparation to which the cosmetic composition of the presentinvention can be added include, but are not limited to, skin lotion,skin softener, skin toner, convergent lotion, softening lotion,nutritional lotion, astringent, lotion, milk lotion, moisturizinglotion, nourishing lotion, body cream, massage cream, nourishing cream,moisture cream, hand cream, essence, nourishing essence, pack, soap,shampoo, cleansing foam, cleansing lotion, cleansing Cream, body lotion,body cleanser, treatment, serum, milk, press powder, loose powder, eyeshadow, and the like.

The content of the polypeptide of the present invention contained in thecosmetic composition of the present invention can be in the range of0.0001 to 50% by weight, preferably 0.01 to 10% by weight based on thetotal weight of the cosmetic composition.

In addition, the present invention provides a food composition forpromoting hair growth, or preventing and improving alopecia comprisingone or more polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

The present invention also provides a food composition for promotinghair growth, or preventing and improving alopecia consisting of one ormore polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

The present invention also provides a food composition for promotinghair growth, or preventing and improving alopecia consisting essentiallyof one or more polypeptide as an active ingredient selected from thegroup consisting of a polypeptide consisting of 4 to 21 consecutiveamino acids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

Preferably, in the food composition of the present invention, thepolypeptide can be a polypeptide consisting of an amino acid sequenceselected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ IDNO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.

In addition, the present invention provides a food composition forpromoting hair growth, or preventing and improving alopecia comprising apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

The present invention also provides a food composition for promotinghair growth, or preventing and improving alopecia consisting of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

The present invention also provides a food composition for promotinghair growth, or preventing and improving alopecia consisting essentiallyof a polypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

The food composition of the present invention includes all forms such asfunctional food, nutritional supplement, health food and food additives.These types can be prepared in various forms according to conventionalmethods known in the art. For example, as the health food, the foodcomposition itself of the present invention can be prepared in the formof tea, juice, and drink, and can be ingested as granulated,encapsulated, and powdered form. In addition, the food composition ofthe present invention can be prepared in the form of a composition bymixing with a known substance or active ingredient known to have theeffect of promoting hair growth, or preventing or improving alopecia. Inaddition, the functional foods also include beverages (includingalcoholic beverages), fruits and their processed foods (e.g., cannedfruits, bottled, jam, maalmalade, etc.), fish, meats and processed foods(e.g., ham, etc.), breads and noodles (e.g., udon, buckwheat noodles,ramen noodles, spaghetti, macaroni, etc.), juice, various drinks,cookies, yeot, dairy products (e.g., butter, cheeses, etc.), edibleplant oils, margarine, vegetable protein, retort food, frozen food,various kinds of seasoning (e.g., soybean paste, soy sauce, sauce,etc.).

The preferred content of the food composition of the polypeptide of thepresent invention is not particularly limited, but is preferably 0.01 to50% by weight in the finally prepared food. In order to use the foodcomposition of the present invention in the form of a food additive, itcan be prepared in the form of powder or concentrate.

In addition, the present invention provides use of one or morepolypeptide selected from the group consisting of a polypeptideconsisting of 4 to 21 consecutive amino acids from the amino acidsequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th)to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ IDNO: 1, and a polypeptide consisting of an amino acid sequence having 70%or more sequence homology with the polypeptide for preparing an agentfor promoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia.

In addition, the present invention provides a method for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia, the method comprising administering toa subject in need thereof an effective amount of composition comprisingone or more polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

The present invention also provides a method for promoting hair growth,promoting proliferation of hair follicle stem cells, or preventing andtreating alopecia, the method comprising administering to a subject inneed thereof an effective amount of composition consisting of one ormore polypeptide as an active ingredient selected from the groupconsisting of a polypeptide consisting of 4 to 21 consecutive aminoacids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

The present invention also provides a method for promoting hair growth,promoting proliferation of hair follicle stem cells, or preventing andtreating alopecia, the method comprising administering to a subject inneed thereof an effective amount of composition consisting essentiallyof one or more polypeptide as an active ingredient selected from thegroup consisting of a polypeptide consisting of 4 to 21 consecutiveamino acids from the amino acid sequence of SEQ ID NO: 1, wherein thepolypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA)of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting ofan amino acid sequence having 70% or more sequence homology with thepolypeptide.

In addition, the present invention provides use of a polypeptideconsisting of amino acid sequence of SEQ ID NO: 1 for preparing an agentfor promoting hair growth, promoting proliferation of hair follicle stemcells, or preventing and treating alopecia.

In addition, the present invention provides a method for promoting hairgrowth, promoting proliferation of hair follicle stem cells, orpreventing and treating alopecia, the method comprising administering toa subject in need thereof an effective amount of composition comprisinga polypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

The present invention provides a method for promoting hair growth,promoting proliferation of hair follicle stem cells, or preventing andtreating alopecia, the method comprising administering to a subject inneed thereof an effective amount of composition consisting of apolypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

The present invention provides a method for promoting hair growth,promoting proliferation of hair follicle stem cells, or preventing andtreating alopecia, the method comprising administering to a subject inneed thereof an effective amount of composition consisting essentiallyof a polypeptide consisting of amino acid sequence of SEQ ID NO: 1 as anactive ingredient.

The “effective amount” of the present invention refers to an amountthat, when administered to an individual, represents an improvement,treatment, or prevention effect of alopecia and effect of promoting hairgrowth, and the “individual” includes an animal, preferably a mammal, inparticular may be an animal comprising human, an animal-derived cell,tissue, organs, and the like. The subject can be a patient requiring theeffect.

The ‘preparation or composition’ of the present invention can be in theform of a food composition, a cosmetic composition, a pharmaceuticalcomposition, and the like, as described above.

The term “comprising” of the present invention is used synonymously with“containing” or “characterized in that” and does not exclude additionalcomponent elements or method steps not mentioned in the composition ormethod. The term “consisting of” refers to exclude additional elements,steps or components not otherwise mentioned. The term “consistingessentially of” is intended to encompass component elements or steps,etc., which, in addition to the described component elements or steps,do not substantially affect their underlying properties.

Advantageous Effects

Accordingly, the present invention provides a novel fragment of AIMP1protein and a composition comprising the same as an active ingredientfor promoting hair growth, or preventing, improving and treatingalopecia. The novel polypeptide according to the present invention andthe composition comprising the same as an active ingredient can be usedfor improving and preventing alopecia, and promoting hair growth,because it enhances hair growth.

BRIEF DESCRIPTION OF THE DRAWINGS

In FIG. 1, the upper part of the figure shows an outline of a mouseexperiment for confirming the in vivo hair growth promoting effect ofthe polypeptide of the present invention, and the lower part of thefigure shows a state in which hair of a dorsal skin of the mouse isremoved before the beginning of the experiment (Day 0, left panel), andabout two weeks later in which hair of the dorsal skin of the mouse grew(Day 13, right panel) [Control (Con): 20% Glycerol/PBS; 3% Minoxidil(MNX, 140 mM); Neo-Pep polypeptide (polypeptide of SEQ ID NO: 1, 100nM); FGF7 (100 nM)].

In FIG. 2, in the left part of the figure, the cross-sectional andlongitudinal section images of the skin tissue and the hair follicleregion observed through a phase contrast microscope are shown in orderto compare the hair growth in the control group and the Neo-Peppolypeptide (polypeptide of SEQ ID NO: 1) treated group at Day 13 afterdepilation, and the right part of the figure shows a graph comparing thenumber of hair follicle cell in anagen phase and the thickness of thedermis quantitatively.

FIG. 3 shows the cross-sectional images of the skin tissue and hairfollicle region observed through a phase contrast microscope in order tocompare the hair growth in the control group and the Neo-Pep polypeptide(polypeptide of SEQ ID NO: 1) treated group at Day 6 after depilation.As can be seen from the results of the proliferation of BrdU (cellproliferation marker), β-catenin (signaling marker of hair folliclecell) and Cytokeratin 15 (hair follicle stem cell marker), it wasconfirmed that the anagen phase starts earlier in Neo-Pep polypeptide(polypeptide of SEQ ID NO: 1) treated group than the control group[Control (Con): 20% Glycerol/PBS; Neo-Pep polypeptide (polypeptide ofSEQ ID NO: 1, 100 nM)].

FIG. 4 shows in vitro assay results showing that the Neo-Pep polypeptide(polypeptide of SEQ ID NO: 1) induces the proliferation of CD34+ hairfollicle stem cells in a concentration dependent manner (1 nM, 10 nM,100 nM, 1000 nM).

FIG. 5 is a graph showing in vitro assay results that the Neo-Peppolypeptide (polypeptide of SEQ ID NO: 1, 100 nM) induces theproliferation of CD34+ hair follicle stem cells through the β-cateninpathway, and it was confirmed that the mRNA expression of AXIN, CD44 andTCF which are target gene of β-catenin was increased by treatment ofpolypeptide of the present invention[Control (Con): 20% Glycerol/PBS;Neo-Pep polypeptide (polypeptide of SEQ ID NO: 1, 100 nM)].

FIG. 6 is images showing the effect of promoting hair growth usingC3H/HeJ mice having a skin graft cell-induced alopecia areata [(Controltreated mice: 100 μl of 20% glycerol/PBS); Neo-Pep polypeptide-treatedgroup (Peptide-treated mice, 100 μl of 100 nM Neo-Pep polypeptide (SEQID NO: 1) in 20% glycerol/PBS).

FIG. 7 is images showing the state of hair follicles and presence orabsence of inflammation in the skin tissue sections of C3H/HeJ micehaving a skin graft cell-induced alopecia areata [(Control treated mice:100 μl of 20% glycerol/PBS); Neo-Pep polypeptide-treated group(Peptide-treated mice, 100 μl of 100 nM Neo-Pep polypeptide (SEQ IDNO: 1) in 20% glycerol/PBS).

FIG. 8 is a graph showing in vitro assay results confirming the effecton promoting the proliferation of CD34+ hair follicle stem cells withthe Neo-Pep polypeptide of the present invention (SEQ ID NO: 1) and itsfragment having 19 or 20 amino acids (N1: SEQ ID NO: 2, N2: SEQ ID NO:3, N3: SEQ ID NO: 4, N4: SEQ ID NO: 5, N5: SEQ ID NO: 6, N6: SEQ ID NO:7, N7: SEQ ID NO: 8 and N8: SEQ ID NO: 9)(each peptide was treated atthe concentration of 100 nM).

FIG. 9 is images confirming the in vivo hair growth promoting effect offragments of Neo-Pep polypeptide of the present invention (SEQ ID NO:1), wherein the fragments consist of 15 amino acids (N9: SEQ ID NO: 10,N10: SEQ ID NO: 11, N11: SEQ ID NO: 12, N12: SEQ ID NO: 13, N13: SEQ IDNO: 14 and N14: SEQ ID NO: 15) [Control (con): 20% Glyceol/PBS; 3%Minoxidil (MNX, 140 mM); N9 to N14 polypeptide fragments (SEQ ID NO: 10to 15, 100 nM)]

MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention will be described in detail.

However, the following examples are merely for illustrating the presentinvention and are not intended to limit the scope of the presentinvention.

Method

1. In Vivo Study

The hair of the dorsal skin of mice (7 weeks old male C57BL6, purchasedfrom Orient Bio Inc.) was cut out with a clipper, and hair removal cream(Niclean, Ildong Pharmaceutical) was applied. The depilated area wasabout 2×2.5 cm. Mice were treated with 20% glycerol/PBS (control group),3% Minoxidil (MNX, 140 mM), FGF7 (100 nM) or Neo-Pep of the presentinvention (polypeptide of SEQ ID NO: 1, 100 nM), respectively, once aday in 80 μl using brush, for 13 days (n=6 per group).

2. Hematoxylin-eosin (H&E) Staining

Skin samples of 7 weeks old male C57BL6 mice (purchased from Orient BioInc.) were collected and placed in a cryomold using an OCT compound(Tissue-Tek) and stored at −80° C. in a freezer. After tissue sectionswere prepared with Microm HM 525 (Thermo Scientific), the tissuesections prepared in the slide glass were fixed with 4% paraformaldehydefor 10 minutes, washed twice with PBS for 5 minutes, and then stainedwith 50 μl of hematoxylin solution (Sigma Aldrich) for 6 minutes andwashed with water and PBS for 5 minutes. Then, stained with eosin (SigmaAldrich), briefly washed with water and washed with PBS for 5 min, thenbriefly twice with 95% ethanol and 100% ethanol, respectively. Aftertreatment with xylene (Duksan) twice for 2 min, the stained tissuesections were covered with cover slides and fixed.

3. Separation of CD34+ Cells for Proliferation Assay

The hair of the dorsal skin of 7 weeks old male C57BL6 mice (purchasedfrom Orient Bio Inc.) were cut with a clipper and skin tissue samples ofthe depilated dorsal region of the mice were collected. The collectedskin tissue samples were immersed in medium using collagenase, DNase I,and hyaluronidase, and cells were isolated using Gentle MACSTMDissociator (Miltenyi Biotec). After the cells were separated, theseparated cells were incubated with a mouse CD34-Biotin antibody(Miltenyi Biotec). Cells and antibody solutions were incubated withstreptavidin microbeads (Miltenyi Biotec) and then separated using LScolumn (Miltenyi Biotec). The separated cells were cultured in DMEMmedium containing 10% FBS, 1% penicillin/streptomycin solution inhumidified air of 95% O₂ and 5% CO₂ at 37° C.

4. BrdU Proliferation Assay

Cell proliferation can be confirmed using the BrdU cell proliferationassay kit (Cell Signaling). Proliferation assays were performed usingprotocols presented by Miltenyi Biotec. Briefly, the cells wereincubated with BrdU for 2 h. The primary BrdU detection antibody wasincubated for 1 hour and the secondary anti-mouse IgG, HRP-conjugateantibody was incubated for 30 minutes.

5. In Vitro Hair Growth Assay and Observation of mRNA Expression Level

A hair growth in vitro assay was performed using the

Cyquant Assay (Thermo Fisher). The assay conditions were as follows:Cell—CD34+ hair follicle stem cells; Culture plate—96 well plate; Cellnumber—3×10³ cells/well; Concentration of final polypeptide—100 nM;incubation time 24 hours.

In order to confirm the induction of CD34+ hair follicle stem cellproliferation through β-catenin pathway, mRNA expression levels ofβ-catenin target genes AXIN, CD44 and TCF7 were confirmed by thefollowing method. Specifically, each test substance was treated andCD34+ cells were cultured for 8 hours. Then, the cultured cells werecollected, RNA was isolated using GeneJET RNA purification kit (ThermoFisher, K0731), and cDNA was synthesized with the Maxima first strandcDNA synthesis kit (Thermo Fisher, K1642). qRT-PCR was performed usingeach of the gene-specific primers (TCF7: 5′-ATCCTTGATGCTGGGATTCTG-3′(SEQ ID NO: 36) and 5′-CTTCTCTTGCCTTGGGTTCTG-3′ (SEQ ID NO: 37), AXIN2:5′-CTCCTTGGAGGCAAGAGC-3′ (SEQ ID NO: 38) and 5′-GGCCACGCAGCACCGCTG-3′(SEQ ID NO: 39), CD44: 5′-CCACAGCCTCCTTTCAATAACC-3′ (SEQ ID NO: 40) and5′-GGAGTCTTCGCTTGGGGTA-3′ (SEQ ID NO: 41)), Maxima SYBR green/ROX qPCRmaster mix(Thermo Fisher, K0222) and 7500 Real-time PCR system (AppliedBiosystems, 2720; condition: 40 cycles, 2 step (95° C. for 15 sec, and54° C. for 60 sec). The expression level of each gene was calculated bythe ΔΔC_(T) method.

6. Histological Analysis

A skin sample of 7 weeks old male C57BL6 mice (purchased from Orient BioInc.) was collected and placed in a paraffin block. IHC(Immunohistochemistry) was performed using Cytokeratin 15 antibody(Abcam), BrdU antibody (Novusbio), and β-catenin antibody.

For reference, β-catenin is a hair follicle signaling marker,Cytokeratin 15 is a hair follicle stem cell marker, and BrdU is a cellproliferation marker.

EXAMPLE 1 Hair Growth Promoting Effect of the Polypeptide of the PresentInvention

The effects of the polypeptide according to the present invention inpromoting hair growth and preventing or treating alopecia in vivo wereconfirmed using mice. The hair was removed from the dorsal skin of themice, and the hair regrowth pattern after treatment with the polypeptideaccording to the present invention was compared with the control group(see FIG. 1).

Specifically, the hair of the dorsal skin of a mouse (7 weeks old maleC57BL6, purchased from Orient Bio Inc.) was cut out with a clipper, andhair removal cream (Niclean, Ildong Pharmaceutical) was applied. Thedepilated area was about 2×2.5 cm. Mice were treated with 20%glycerol/PBS(control group), 3% Minoxidil (MNX, 140 mM), FGF7 (100 nM)or Neo-Pep of the present invention (polypeptide of SEQ ID NO: 1, 100nM), respectively, once a day in 80 μl using brush, for 13 days (n=6 pergroup). For comparative observation, the dorsal skin of the mouse wasphotographed before and after the beginning of the test.

As can be seen from the images of the skin of the mice at the bottom ofFIG. 1, 13 days after depilation of dorsal skin, the dorsal hair of themice treated with the polypeptide of the present invention “Neo-Pep”(polypeptide of SEQ ID NO: 1) grew much more than that of control andother experimental groups (i.e., MNX and FGF7).

In addition, dorsal skin samples of the mice were collected and placedin a cryomold using an OCT compound (Tissue-Tek) and stored at −80° C.in a freezer. After tissue sections were prepared with Microm HM 525(Thermo Scientific), the tissue sections prepared in the slide glasswere fixed with 4% paraformaldehyde for 10 minutes, washed twice withPBS for 5 minutes, and then stained with 50 μl of hematoxylin solution(Sigma Aldrich) for 6 minutes and washed with water and PBS for 5minutes. Then, stained with eosin (Sigma Aldrich), briefly washed withwater and washed with PBS for 5 min, then briefly twice with 95% ethanoland 100% ethanol, respectively. After treatment with xylene (Duksan)twice for 2 min, the stained tissue sections were covered with coverslides and fixed. The number of hair follicles of anagen phase (growthphase) was counted and compared quantitatively in dorsal skin sectionsof each group stained with hematoxylin and eosin (H & E).

As shown in FIG. 2, as a result of comparing the number of hairfollicles of anagen phase in the mouse skin sections stained with H & E,in the dorsal skin of the mice treated with the polypeptide of thepresent invention “Neo-Pep” (polypeptide of SEQ ID NO: 1), more thantwice as much hair follicles of anagen phase were observed as comparedwith the control (Con), and the dermis thickness was also much thicker.

Through the test result, it was confirmed that the polypeptide of thepresent invention “Neo-Pep” (SEQ ID NO: 1) has effect on promoting hairgrowth, and improving and treating alopecia in vivo.

EXAMPLE 2 Effect of the Polypeptide of the Present Invention on InducingProliferation of Hair Follicle Stem Cell Through β-catenin Signaling

β-catenin is a very important protein for hair growth and a veryimportant factor in follicular stem cell proliferation playing a role asa signaling marker for hair follicle cells. In addition, Cytokeratin 15acts as a biomarker of hair follicle stem cells, and BrdU is known to bea factor that plays a role as a cell growth marker. FIG. 3 shows thecross-sectional images of the skin tissue and hair follicle regionobserved through a phase contrast microscope in order to compare thehair growth in the control group and the Neo-Pep polypeptide(polypeptide of SEQ ID NO: 1) treated group at Day 6 after depilation.As can be seen from the results of the BrdU (cell proliferation marker),β-catenin (signaling marker of hair follicle cell) and Cytokeratin 15(hair follicle stem cell marker), it was confirmed that the anagen phasestarts earlier in Neo-Pep polypeptide (polypeptide of SEQ ID NO: 1)treated group than the control group.

In addition, as can be seen from the graph of in vitro assay of hairgrowth in FIG. 4, the Neo-Pep polypeptide (polypeptide of SEQ ID NO: 1)induced proliferation of CD34+ hair follicle stem cells in adose-dependent manner (1 nM, 10 nM, 100 nM and 1000 nM). As shown in thein vitro assay result graph of FIG. 5, it was confirmed that the Neo-Peppolypeptide (polypeptide of SEQ ID NO: 1, 100 nM) induces theproliferation of CD34+ hair follicle stem cells through the β-cateninpathway. Specifically, when the Neo-Pep polypeptide (polypeptide of SEQID NO: 1, 100 nM) according to the present invention is used, the mRNAexpression level of AXIN, CD44 and TCF7, which are the target genes ofβ-catenin, increased 5-fold compared to the control group.

EXAMPLE 3 Effect on Promoting Hair Growth in Alopecia Areata Mouse Model

Alopecia areata is known to be a cell-mediated autoimmune disease thattargets hair follicles of anagen phase in various mammalian species. Inhumans, alopecia areata is divided into three classes: alopecia areata(patchy hair loss), alopecia totalis (hair loss on the head), andalopecia universalis (total body hair loss).

In order to confirm the effect of the polypeptide of the presentinvention on the human hair growth cycle, C3H/HeJ mouse (JacksonLaboratory, USA) was used as an animal model reflecting the pathologicalstate of human alopecia areata. The advantage of using the C3H/HeJ mouseis that when full thickness skin graft is applied to an aged mousehaving alopecia areata from young age, patchy alopecia develops within 8to 10 weeks, and after 20 weeks, alopecia extends to the whole body skinand result in a chronic state of alopecia universalis.

In this test, C3H/HeJ female mice having alopecia universalis that wasinduced 25 weeks after skin transplantation as described above wereused. Without any pretreatment such as shaving or depilation, controlgroup (Control-treated mice, 100 μl of 20% glycerol/PBS) and Neo-Peppolypeptide treated group (Peptide-treated mice, 100 μl of 100 nMNeo-Pep polypeptide (SEQ ID NO: 1) in 20% glycerol/PBS) were treatedwith each test material topically around the alopecia region usingbrush, once daily, for 14 weeks. Control group and Neo-Pep treated groupconsisted of 4 mice, respectively.

Photographs were taken every 2 weeks from the beginning of theexperiment. FIG. 6 shows the state of hair growth of mice at 1 week and14 weeks after the beginning of the experiment. In the case of Neo-Peppolypeptide-treated group (peptide-treated mice, 100 nM Neo-Peppolypeptide (SEQ ID NO: 1) in 20% glycerol/PBS), hair began to growagain after 11 weeks of administration, and mild to moderate hair growthwas observed in 3 out of 4 mice (# 11, # 13, and # 14 mice) showingconsistent hair growth effect. In contrast, the control group showedmild hair growth effect in only 1 mouse (# 18 mouse) out of 4 mice,alopecia of 2 mice (# 15 and # 17 mouse) became more severe, and 1 (# 16mouse) died before the end of the experiment, thus showing no consistenthair growth effect.

Meanwhile, in the images of the skin tissue of the mouse in FIG. 7, theskin tissue at the alopecia area and the area without alopecia around itwas collected, fixed in Fekete's acid alcohol formalin and analyzed forH&E staining. And FIG. shows results confirming the presence or absenceof deformation or inflammation, and the state of hair follicle.

As can be seen from FIG. 7, especially in the skin tissue of the controlgroup, complex infiltration of inflammatory cells in the hair folliclesand around the hair follicles was observed, and especially lymphocyteinfiltration was frequently found. These are main characteristics usedfor diagnosing alopecia areata. And follicular dystrophy is a phenomenonthat occurs frequently in alopecia areata, which means that hairfollicles are twisted and deformed or have weak or disrupted hair shaft.

As can be seen from FIG. 7, inflammation and deformed hair shaft weredeveloped in the skin of the control group. On the other hand, thedevelopment of inflammation and deformed hair shaft was significantlylower in Neo-Pep polypeptide treated group compared to the controlgroup. The overall alopecia state changes depending on the hair shaftbreakage near the skin surface or skin surface. And the alopecia statewas more clearly observed in the control group where the malformed hairshaft such as hair shaft breakage was relatively more.

EXAMPLE 4 Effect of the Polypeptide of the Present Invention onProliferation of Hair Follicle Stem Cells

The present inventor prepared N1 (SEQ ID NO: 2), N2 (SEQ ID NO: 3), N3(SEQ ID NO: 4), N4 (SEQ ID NO: 5), N5 (SEQ ID NO: 6), N6 (SEQ ID NO: 7),N7 (SEQ ID NO: 8) and N8 (SEQ ID NO: 9) in order to identify peptidefragments having the effect on promoting hair growth and improvingalopecia in the Neo-Pep polypeptide (SEQ ID NO: 1) in which the hairgrowth promoting effect was confirmed in the above Examples.

Table 1 below shows the amino acid sequence, PI and Tm of Neo-Pep (SEQID NO: 1) and its fragments, N1 (SEQ ID NO: 2), N2 (SEQ ID NO: 3), N3(SEQ ID NO: 4), N4 (SEQ ID NO: 5), N5 (SEQ ID NO: 6), N6 (SEQ ID NO: 7),N7 (SEQ ID NO: 8) and N8 (SEQ ID NO: 9).

TABLE 1 Polypeptide (SEQ ID) Amino acid sequence PI Tm Neo-Pep (SEQ ID6                                      46 9.33 >65 NO: 1)AVLKRLEQKGAEADQIIEYLKQQVSLL KEKA ILQATLREEK N1 AVLKRLEQKGAEADQIIEYL 4.6455~65 (SEQ ID NO: 2) N2   LKRLEQKGAEADQIIEYLKQ 7.05 <55 (SEQ ID NO: 3)N3         KGAEADQIIEYLKQQVSLLK 7.01 55~65 (SEQ ID NO: 4) N4          AEADQIIEYLKQQVSLLKEK 4.64 55~65 (SEQ ID NO: 5) N5                IEYLKQQVSLL KEKA ILQAT 9.53 >65 (SEQ ID NO: 6) N6                  YLKQQVSLL KEKA ILQATLR 10.56 >65 (SEQ ID NO: 7) N7                    KQQVSLL KEKA ILQATLREE 9.8 >65 (SEQ ID NO: 8) N8                      QVSLL KEKA ILQATLREEK 9.8 55~65 (SEQ ID NO: 9)

For reference, the polypeptide Neo-Pep (SEQ ID NO: 1) of the presentinvention corresponds to the 6^(th) to 46^(th) amino acid residue in theAIMP1 protein (SEQ ID NO: 16).

MANNDAVLKRLEQKGAEADQIIEYLKQQVSLLKEKAILQATLREEKKLRVENAKLKKEIEELKQELIQAEIQNGVKQIPFPSGTPLHANSMVSENVIQSTAVTTVSSGTKEQIKGGTGDEKKAKEKIEKKGEKKEKKQQSIAGSADSKPIDVSRLDLRIGCIITARKHPDADSLYVEEVDVGEIAPRTVVSGLVNHVPLEQMQNRMVILLCNLKPAKMRGVLSQAMVMCASSPEKIEILAPPNGSVPGDRITFDAFPGEPDKELNPKKKIWEQIQPDLHTNDECVATYKGVPFEVKGKGV CRAQTMSNSGIK

CD34+ hair follicle stem cells in vitro assay and BrdU proliferationassay method described above were used. As can be seen in FIG. 8 inwhich the relative number of CD34+ hair follicle stem cell was compared,Neo-Pep (SEQ ID NO: 1), and its fragments (N5 (SEQ ID NO: 6), N6 (SEQ IDNO: 7), N7 (SEQ ID NO: 8) and N8 (SEQ ID NO: 9)) comprising 28^(th) to31^(st) amino acid residue (KEKA) of Neo-Pep polypeptide and consistingof 19 or 20 consecutive amino acids induced proliferation of CD34+ hairfollicle stem cells.

On the other hand, fragments (N1 (SEQ ID NO: 2), N2 (SEQ ID NO: 3), N3(SEQ ID NO: 4) and N4 (SEQ ID NO: 5)) of Neo-Pep (SEQ ID NO: 1)consisting of 20 consecutive amino acids without 28^(th) to 31^(st)amino acid residue (KEKA) of Neo-Pep polypeptide didn't show any effecton inducing proliferation of CD34+ hair follicle stem cells.

Through the above results, it was confirmed that not only Neo-Peppolypeptide (SEQ ID NO: 1) but also polypeptide fragments which comprise28^(th) to 31^(st) amino acid residue of Neo-Pep polypeptide as anactive amino acid residue and consist of consecutive amino acids haveeffect on promoting hair growth and improving alopecia.

EXAMPLE 5 Effect of the Polypeptide of the Present Invention onPromoting In Vivo Hair Growth

The present inventor prepared N9 (SEQ ID NO: 10), N10 (SEQ ID NO: 11),N11 (SEQ ID NO: 12), N12 (SEQ ID NO: 13), N13 (SEQ ID NO: 14) and N14(SEQ ID NO: 15), which are polypeptide fragments consisting of 15 aminoacids, in order to further identify peptide fragments having the effecton promoting hair growth and improving alopecia in the Neo-Peppolypeptide (SEQ ID NO: 1) in which the hair growth promoting effect wasconfirmed in the above Examples.

Table 2 below shows the amino acid sequence, PI and Tm of Neo-Pep (SEQID NO: 1) and its fragments, N9 (SEQ ID NO: 10), N10 (SEQ ID NO: 11),N11 (SEQ ID NO: 12), N12 (SEQ ID NO: 13), N13 (SEQ ID NO: 14) and N14(SEQ ID NO: 15).

TABLE 2 Polypeptide (SEQ ID) Amino acid sequence PI Tm Neo-Pep6                                      46 9.33 >65 (SEQ IDAVLKRLEQKGAEADQIIEYLKQQVSLL KEKA ILQATLREEK NO: 1) N9 AVLKRLEQKGAEADQ7.08 >65 (SEQ ID NO: 10) N10            EADQIIEYLKQQVSL 3.66 >65 (SEQ IDNO: 11) N11             ADQIIEYLKQQVSLL 3.99 >65 (SEQ ID NO: 12) N12                IEYLKQQVSLL KEKA 9.53 >65 (SEQ ID NO: 13) N13                    KQQVSLL KEKA ILQA 10.41 >65 (SEQ ID NO: 14) N14                          L KEKA ILQATLREEK 9.8 <55 (SEQ ID NO: 15)

As can be seen in FIG. 9 (dorsal skin images of mice at 13 days afterdepilation using the same method as in Example 1), dorsal hair of themouse group treated with the polypeptide fragments of the presentinvention (N12 (SEQ ID NO: 13), N13 (SEQ ID NO: 14) and N14 (SEQ ID NO:15)) comprising 28^(th) to 31^(st) amino acid residue (KEKA) of Neo-Peppolypeptide and consisting of 15 consecutive amino acids grew much morethan control group (Con, 20% glycerol/PBS treated group), and grew evensimilar to or much more than positive control group (MNX, 3% Minoxidiltreated group).

On the other hand, fragments (N9 (SEQ ID NO: 10), N10 (SEQ ID NO: 11)and N11 (SEQ ID NO: 12)) of Neo-Pep (SEQ ID NO: 1) consisting of 15consecutive amino acids without 28^(th) to 31^(st) amino acid residue(KEKA) of Neo-Pep polypeptide didn't show such effect.

Through the above results, it was further confirmed that polypeptidefragments such as N12 (SEQ ID NO: 13), N13 (SEQ ID NO: 14) and N14 (SEQID NO: 15), which comprise 28^(th) to 31^(st) amino acid residue ofNeo-Pep polypeptide (SEQ ID NO: 1) as an active amino acid residue andconsist of consecutive amino acids, have effect on promoting hair growthand improving alopecia. Thus, it was confirmed that comprising the28^(th) to 31^(st) amino acid residue (KEKA) of the Neo-Pep polypeptide(SEQ ID NO: 1) as an active site is essential for effect on promotinghair growth and improving alopecia.

1. A polypeptide consisting of 4 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1, or a polypeptide consisting of an amino acid sequence having 70% or more sequence homology with the polypeptide.
 2. The polypeptide of claim 1, wherein the polypeptide consists of 10 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1 and comprises the 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ ID NO:
 1. 3. The polypeptide of claim 1, wherein the polypeptide consists of 15 to 20 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1 and comprises the 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ ID NO:
 1. 4. The polypeptide of claim 1, wherein the polypeptide consists of amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO:
 15. 5. A polynucleotide encoding the polypeptide of claim
 1. 6. The polynucleotide of claim 5, wherein the polynucleotide consists of nucleotide sequence selected from the group consisting of SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 30 and SEQ ID NO:
 31. 7. A composition comprising as an active ingredient one or more polypeptide selected from the group consisting of a polypeptide consisting of 4 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequence having 70% or more sequence homology with the polypeptide.
 8. The composition of claim 7, wherein the polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO:
 15. 9. The composition of claim 7, wherein the composition further comprises a compound or pharmaceutically acceptable salt thereof selected from the group consisting of minoxidil, cromakalin, pinacidil, naminidil, diphenylcyclopropenone, tricomin, cyproterone acetate, danazol, flutamide; 5-alpha reductase inhibitors selected from the group consisting of finasteride, turosteride, LY-191704, MK-306 and dutasteride; striazines, benzopyrans, pyridinopyrans and thiane-1-oxides.
 10. The composition of claim 7, wherein the composition is a pharmaceutical composition, a cosmetic composition, or a food composition. 11-14. (canceled)
 15. A method for promoting hair growth, promoting proliferation of hair follicle stem cells, or preventing and treating alopecia, the method comprising administering to a subject in need thereof an effective amount of a composition comprising one or more polypeptide as an active ingredient selected from the group consisting of a polypeptide consisting of 4 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28^(th) to 31^(st) amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1, and a polypeptide consisting of an amino acid sequence having 70% or more sequence homology with the polypeptide.
 16. A composition comprising a polypeptide consisting of amino acid sequence of SEQ ID NO: 1 as an active ingredient.
 17. The composition of claim 16, wherein the composition is a pharmaceutical composition, a cosmetic composition or a food composition. 18-19. (canceled)
 20. A method for promoting hair growth, promoting proliferation of hair follicle stem cells, or preventing and treating alopecia, the method comprising administering to a subject in need thereof an effective amount of composition comprising a polypeptide consisting of amino acid sequence of SEQ ID NO: 1 as an active ingredient. 